EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies

Gerry Gin Wai Kwok iD, Jenny Lo, Tiffany Hoi Wing Fung iD

Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1427-1435

DOI: 10.1111/jgh.70353 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 24.03.2026. Verfasst von Gerry Gin Wai Kwok und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Molecular Targeted Therapy. Die Arbeit nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced pancreatic cancer remains a leading cause of cancer death in developed countries and has seen limited progress in systemic therapy over the past decade. This review highlights recent first‐line standard of care treatment options and explores biomarker‐driven strategies, particularly homologous recombination deficiency for personalized treatment selection. We emphasize how the adoption of tumor next‐generation sequencing is shaping precision therapy, including tumor‐agnostic targets such as NRG1 fusions and BRAF alterations in KRAS wild‐type tumors. Advances in KRAS inhibitors, PROTACs, tumor treating fields, and PRMT5 inhibitors for MTAP‐deleted tumors are rapidly expanding potential treatment options for patients. Emerging immunotherapies targeting Claudin18.2 and CXCR4 offer hope to overcome tumor resistance. Together, these strategies underscore the promise of molecular stratification, synthetic lethality, and novel targets to improve pancreatic cancer survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsMolecular Targeted TherapyHumansImmunotherapyPrecision MedicineBiomarkers, TumorProto-Oncogene Proteins p21(ras)Receptors, CXCR4Proteolysis Targeting ChimeraNeuregulin-1

Stichwörter der Autor:innen

CAR‐TCXCR4ESCATKRASMTAPNRG1PDACPRMT5PROTACpancreatic cancer

Substanzen

Biomarkers, TumorProto-Oncogene Proteins p21(ras)Receptors, CXCR4Proteolysis Targeting ChimeraKRAS protein, humanCXCR4 protein, humanNRG1 protein, humanNeuregulin-1

Autor:innen und Institutionen

  • Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.

ORCID-Profile: Gerry Gin Wai Kwok, Tiffany Hoi Wing Fung

Zitieren

APA

Kwok, G. G. W., Lo, J., & Fung, T. H. W. (2026). Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies. Journal of Gastroenterology and Hepatology, 41(5), 1427-1435. https://doi.org/10.1111/jgh.70353

Vancouver

Kwok GGW, Lo J, Fung THW. Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies. Journal of Gastroenterology and Hepatology. 2026;41(5):1427-1435. doi:10.1111/jgh.70353

BibTeX
@article{Kwok2026,
  author = {Kwok, Gerry Gin Wai and Lo, Jenny and Fung, Tiffany Hoi Wing},
  title = {Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {5},
  pages = {1427--1435},
  doi = {10.1111/jgh.70353}
}
Kostenlos starten →